Agenus Inc.
N/A
USD
N/A
N/A
...
Chart
Financials
Description
AGEN Company Description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
AGEN Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view AGEN Smart Score
Score Breakdown
AGEN Company Description
Show More
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of AGEN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AGEN's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on AGEN's company Twitter account
WallStreetBets
Number of mentions of AGEN in WallStreetBets Daily Discussion
AGEN News
Recent insights relating to AGEN
CNBC Recommendations
Recent picks made for AGEN stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in AGEN
Corporate Flights
Flights by private jets registered to AGEN
Our Analysis